Samc Pharm 2 Quiz

Front 1

Calcium Gluconate

Classification
&
Special Considerations

Back 1

Classification:
 Electrolyte solution

Special Considerations:
 Do not administer IM or Sub-Q
 Pregnancy class C

Front 2

Calcium Gluconate

Action

Back 2

Action:

 Counteracts the toxicity of hyperkalemia by stabilizing cardiac cells, reducing fibrillation.

Front 3

Calcium Gluconate

Indications

Back 3

Indications:

 Hyperkalemia
 Hypocalcemia
 Hypermagnesemia

Front 4

Calcium Gluconate

Adverse Effects

Back 4

Effects:

 Tissue necrosis
 Hypotension
 Bradycardia

Front 5

Calcium Gluconate

Contraindications

Back 5

Contraindications:

 Ventricular fib.
 Digitalis toxicity
 Hyperkalemia

Front 6

Calcium Gluconate

Dosage

Back 6

Dosage:

Adult:
 500 to 1000 mg IV,IO at a rate of 1 to 1.5 mL/min max dose 3 g IV/IO.

Pediatric:
 60 to 100 mg/kg IV, IO slowly over 5-10 min. Max dose 3 g IV,IO

Front 7

AMIDATE
(Etomidate)

Classification
&
Special Considerations

Back 7

Classification:
 Hypotonic, anesthesia induction agent

Special Considerations:
 Airway management must be in place

Front 8

AMIDATE
(Etomidate)

Action

Back 8

Action:

 Has a GABA-Like effect

Front 9

AMIDATE
(Etomidate)

Indications

Back 9

Indications:
 RSI
 Pharmacologic assisted intubation
 Induction of anesthesia

Front 10

AMIDATE
(Etomidate)

Adverse Effects

Back 10

Effects:
 Hypotension
 Respiratory depression
 Cardiac arrhythmias

Front 11

AMIDATE
(Etomidate)

Contraindications

Back 11

Contraindications:
 Use in pregnancy only if the benefit out weighs the risk to the fetus
 Do not use during labor
 Do not use while nursing

Front 12

AMIDATE
(Etomidate)

Dosage

Back 12

Dosage:
Adult:
 0.2 – 0.6 slow mg/kg IV,IO over 30-60 seconds
Pediatrics:
 Older than 10, same as adult.
 Younger than 10 not safe

Front 13

Magnesium Sulfate

Classification
&
Special Considerations

Back 13

Classification:
 Electrolyte, tocolytic, mineral

Special Considerations:
 Pregnancy class A

Front 14

Magnesium Sulfate

Action

Back 14

Action:

 Cofactor in neuromuscular transmission and muscular excitability.
 Blocks peripheral neuromuscular transmission to control seizures.
 Peripheral vasodilator

Front 15

Magnesium Sulfate

Indications

Back 15

Indications:

 Torsades de pointes
 Eclampsia
 Status asthmaticus

Front 16

Magnesium Sulfate

Adverse Effects

Back 16

Effects:

 Magnesium toxicity
 Hypotension
 Muscle paralysis

Front 17

Magnesium Sulfate

Contraindications

Back 17

Contraindications:

 AV block
 GI obstruction
 Renal impairment

Front 18

Magnesium Sulfate

Dosage

Back 18

Dosage:

Ventricular Fib/Pulseless V-Tac w/ Torsades de Pointe:
 Adult: 1 to 2 g in 10 ml d5w,IV,IO over 5 min
 Pediatric: 25 to 50 mg/kg IV/IO over 10-20 min
Torsades de Pointe w/pulse or cardiac arrhythmias :
 Adult: 1 to 2 g in 50 to 100 ml d5w,IV,IO over 5-60 min
 Pediatric: 25 to 50 mg/kg IV, IO over 10 to 20 min
Eclampsia and Seizure prophylaxis in pre-eclampsia:
 Adult: 4 to 6 g IV/IO over 20-30 min
Status Asthmaticus:
 Adult: 1.2 to 2 g slow IV/IO over 20 min
 Pediatric: 25 to 50 mg/kg diluted in d5w over 20 min

Front 19

Midazolam
(Versed)

Classification
&
Special Considerations

Back 19

Classification:
 Benzodiazepine, schedule C-IV

Special Considerations:
 Receiving Midazolam
 Pregnancy class D

Front 20

Midazolam
(Versed)

Action

Back 20

Action:

 Binds to benzodiazepine receptors and effects the brain chemical GABA (neurotransmitter)
 Produces short-term CNS depression (sedation, skeletal muscle relaxation, & anticonvulsant)

Front 21

Midazolam
(Versed)

Indications

Back 21

Indications:

 Sedation
 Anxiety
 Skeletal muscle relaxation

Front 22

Midazolam
(Versed)

Adverse Effects

Back 22

Effects:
 Respiratory depression
 Respiratory arrest
 Cardiac arrest

Front 23

Midazolam
(Versed)

Contraindications

Back 23

Contraindications:
 Acute-angle glaucoma
 Pregnancy
 Known sensitivity

Front 24

Midazolam
(Versed)

Dosage

Back 24

Dosage:

Adult:
 1 mg IV,IO (No more than 2.5 mg over a 2 minute period) Max: 5 mg

Pediatric:
 12-16 same as adult
 6-12 0.025 to 0.5 mg/kg IV/IO up to 0.4 not exceeding 10 mg total.
 6 months – 6: 0.05 to 0.1 mg/kg IV/IO up to 0.6 mg/kg
 6 months and under: 0.05 to 0.1 mg/kg IV/IO

Front 25

Pancuronium
(Pavulon)

Classification
&
Special Considerations

Back 25

Classification:
 Non-depolarizing neuromuscular blocker

Special Considerations:
 Pregnancy class C

Front 26

Pancuronium
(Pavulon)

Action

Back 26

Action:

 Antagonizes acetylcholine at the motor end plate, producing skeletal muscle paralysis.

Front 27

Pancuronium
(Pavulon)

Indications

Back 27

Indications:

 To induce neuromuscular blockade facilitate ET intubation.

Front 28

Pancuronium
(Pavulon)

Adverse Effects

Back 28

Effects:

 Muscle paralysis
 Respiratory depression
 Sinus tachycardia

Front 29

Pancuronium
(Pavulon)

Contraindications

Back 29

Contraindications:

 Sensitivity to bromides
 Heart disease
 Renal disease

Front 30

Pancuronium
(Pavulon)

Dosage

Back 30

Dosage:

Adult: 0.04 to 0.1 mg/kg IV,IO; repeat dose 0.01 every 25 to 60 minutes.

Pediatric: Same as adult.

Front 31

Succinylcholine
(Anectine)

Classification
&
Special Considerations

Back 31

Classification:
 Neuromuscular blocker

Special Considerations:
 IV results in neuromuscular block in 30 seconds to 1 minute. IM 2-3 minutes.
 IV in infants and children can potentially result in profound bradycardia or asystole. (bradycardia can be reduced with the administration of atropine)
 Poisoning w/ nerve gas or organophosphates

Front 32

Succinylcholine
(Anectine)

Action

Back 32

Action:

 Antagonizes acetylcholine at the motor end plate on muscle cell, producing muscle skeletal paralysis.

Front 33

Succinylcholine
(Anectine)

Indications

Back 33

Indications:
 Neuromuscular block in order to intubate.

Front 34

Succinylcholine
(Anectine)

Adverse Effects

Back 34

Effects:
 Anaphylactoid reactions
 Respiratory depression
 Cardiac arrhythmias

Front 35

Succinylcholine
(Anectine)

Contraindications

Back 35

Contraindications:
 Burns
 Trauma
 Malignant hyperthermia

Front 36

Succinylcholine
(Anectine)

Dosage

Back 36

Dosage:
Adult:
 IV: 1.5 mg/kg IV/IO
Pediatrics:
IV:
 Adolescents & older 1.5 mg/kg IV/IO
 Small to Infants 2 mg/kg IV/IO

Front 37

Terbutaline
(Brethine)

Classification
&
Special Considerations

Back 37

Classification:
 Adrenergic agonist

Special Considerations:
 Pregnancy class B

Front 38

Terbutaline
(Brethine)

Action

Back 38

Action:

 Stimulates Beta² receptor, producing relaxation of bronchial smooth muscle and bronchodilation.

Front 39

Terbutaline
(Brethine)

Indications

Back 39

Indications:

 Prevention and reversal of bronchospasm.

Front 40

Terbutaline
(Brethine)

Adverse Effects

Back 40

Effects:

 Cardiac arrhythmia
 Arrhythmia exacerbation
 Angina

Front 41

Terbutaline
(Brethine)

Contraindications

Back 41

Contraindications:

 Cardiac disease
 Diabetes
 Seizure disorder

Front 42

Terbutaline
(Brethine)

Dosage

Back 42

Dosage:

Adult: 0.25 mg Sub-Q every 20 minutes for 3 doses.

Pediatric: 0.01 mg/kg Sub-Q every 20 minutes for 3 doses.

Front 43

Vecuronium
(Norcuron)

Classification
&
Special Considerations

Back 43

Classification:
 Neuromuscular blocker

Special Considerations:
 Pregnancy Class C

Front 44

Vecuronium
(Norcuron)

Action

Back 44

Action:

 Antagonizes acetylcholine at the motor end plate, producing muscle skeletal paralysis.

Front 45

Vecuronium
(Norcuron)

Indications

Back 45

Indications:
 Neuromuscular block in order to intubate.

Front 46

Vecuronium
(Norcuron)

Adverse Effects

Back 46

Effects:
 Cardiac ischemia
 angina

Front 47

Vecuronium
(Norcuron)

Contraindications

Back 47

Contraindications:
 Heart disease
 Liver disease
 Sensitivity to bromides

Front 48

Vecuronium
(Norcuron)

Dosage

Back 48

Dosage:
Adult:
 0.08 – 0.1 mg/kg IV,IO
Pediatrics:
 Individualized